Sonoma Pharmaceuticals (Sonoma Pharmaceuticals) COGS-to-Revenue : 0.53 (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Sonoma Pharmaceuticals COGS-to-Revenue?

Sonoma Pharmaceuticals's Cost of Goods Sold for the three months ended in Dec. 2023 was $1.68 Mil. Its Revenue for the three months ended in Dec. 2023 was $3.14 Mil.

Sonoma Pharmaceuticals's COGS to Revenue for the three months ended in Dec. 2023 was 0.53.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Sonoma Pharmaceuticals's Gross Margin % for the three months ended in Dec. 2023 was 46.53%.

Sonoma Pharmaceuticals COGS-to-Revenue Historical Data

The historical data trend for Sonoma Pharmaceuticals's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sonoma Pharmaceuticals COGS-to-Revenue Chart

Sonoma Pharmaceuticals Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

COGS-to-Revenue

Get a 7-Day Free Trial

0.53

0.55

0.65

0.68

0.66

Sonoma Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial															0.72	0.71	0.65	0.64	0.53

Sonoma Pharmaceuticals COGS-to-Revenue Calculation

Sonoma Pharmaceuticals's COGS to Revenue for the fiscal year that ended in Mar. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	8.795	/	13.272
	=	0.66

Sonoma Pharmaceuticals's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	1.678	/	3.138
	=	0.53

Sonoma Pharmaceuticals (NAS:SNOA) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Sonoma Pharmaceuticals's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	1.678 / 3.138
	=	46.53 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Sonoma Pharmaceuticals COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Sonoma Pharmaceuticals's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Sonoma Pharmaceuticals (Sonoma Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sonoma Pharmaceuticals Inc (NAS:SNOA) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

O8Z3:Germany

Address

5445 Conestoga Court, Suite 150, Boulder, CO, USA, 80301

Website

https://www.sonomapharma.com

Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, and other countries.

Executives

Chad Norman White	officer: Interim CFO	645 MOLLY LANE, SUITE 150, WOODSTOCK GA 30189
Jerome J Dvonch	officer: Chief Financial Officer	12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913
Robert Grant Edwards	officer: Chief Financial Officer	1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Poggetto John Dal	officer: Chief Financial Officer	1129 N. MCDOWELL BLVD, PETALUMA CA 94954
Amy Moss Trombly	officer: Interim CEO	1314 MAIN STREET, SUITE 102, LOUSIVILLE CO 80027
Frederick J Sandford	director, officer: CEO and Interim CFO	C/O SONOMA PHARMACEUTICALS, INC., 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Philippe Weigerstorfer	director	1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Robert E Miller	officer: Chief Financial Officer	1129 N. MCDOWELL BLVD., PETALUMA CA 94954
James J Schutz	director, officer: Chief Operating Officer	1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Marc Umscheid	officer: Chief Strategy/Mkt Officer	OCULUS INNOVATIVE SCIENCES, INC., 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Robert Allen Northey	officer: Exec. VP of Res & Devlpment	C/O OCULUS INNOVATIVE SCIENCES, INC., 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Sharon Surrey Barbari	director	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Russell Joseph Harrison	director	OCULUS INNOVATIVE SCIENCES, INC., 1129 NORTH MCDOWELL BLVD., PETALUMA CA 94954
John Mclaughlin	director	OCULUS INNOVATIVE SCIENCES, INC., 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Sameer Harish	other: Officer of Subsidiary (1)	RUTHIGEN, INC., 1129 N. MCDOWELL BLVD, PETALUMA CA 94954